Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial-Reference-Cited by-同舟云学术

Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial

Published:2011-01 Issue:1 Volume:18 Page:17-22
ISSN:1072-3714
Container-title:Menopause
language:en
Short-container-title:

Author:

Goldstein Steven R.,Neven Patrick,Cummings Steven,Colgan Terence,Runowicz Carolyn D.,Krpan Dalibor,Proulx James,Johnson Margot,Thompson David,Thompson John,Sriram Usha

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynecology

Reference14 articles.

1. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.;Fisher;J Natl Cancer Inst,1998

2. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.;Cummings;JAMA,1999

3. Lasofoxifene for postmenopausal women with osteoporosis.;Cummings;N Engl J Med,2010

4. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder.;Reese;Qual Life Res,2003

5. The vaginal profile.;Baden;Tex Med,1968

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer;Nature Reviews Clinical Oncology;2024-08-23

2. Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials;Menopause;2024-04-23

3. The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer;Annals of Oncology;2023-12

4. Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial;Annals of Oncology;2023-12

5. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause;Climacteric;2023-05-18